Exact Sciences(EXAS) ZACKS·2024-11-05 23:30Earnings Performance - Exact Sciences reported a quarterly loss of 0.20, representing an earnings surprise of -5% [1] - The company's loss per share compares to break-even earnings per share a year ago [1] - In the previous quarter, Exact Sciences posted a loss of 0.37 per share, delivering a surprise of 75.68% [1] - Over the last four quarters, the company has surpassed consensus EPS estimates two times [2] Revenue Performance - Exact Sciences posted revenues of 628.34 million in revenues [2] - The company has topped consensus revenue estimates three times over the last four quarters [2] Stock Performance and Market Comparison - Exact Sciences shares have lost about 3.9% since the beginning of the year, underperforming the S&P 500's gain of 19.8% [3] - The stock's immediate price movement will depend on management's commentary on the earnings call [3] Earnings Outlook and Estimate Revisions - The current consensus EPS estimate for the coming quarter is -779.18 million in revenues [7] - For the current fiscal year, the consensus EPS estimate is -2.83 billion in revenues [7] - The estimate revisions trend for Exact Sciences is favorable, translating into a Zacks Rank 1 (Strong Buy) [6] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions [5] Industry Performance - The Medical - Biomedical and Genetics industry is currently in the top 38% of the 250 plus Zacks industries [8] - The top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8] Peer Comparison - Oculis Holding AG (OCS) is expected to report a quarterly loss of 0.28 million, up 13.2% from the year-ago quarter [10]